The impact of glucosamine on age-related macular degeneration in patients: A nationwide, population-based cohort study.

Kathy Ming FengWu-Chien ChienJiann-Torng ChenYi-Hao ChenChi-Hsiang ChungChien-An SunChing-Long Chen

Published in: PloS one (2021)

GlcN treatment can decrease the risk of developing dry type AMD. Further prospective controlled studies are needed to determine the effectiveness of GlcN treatment in patients with AMD and the associated mechanism.

Keyphrases

age related macular degeneration
end stage renal disease
newly diagnosed
ejection fraction
systematic review
chronic kidney disease
peritoneal dialysis
replacement therapy
patient reported